Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
German A. Islan, Boris Rodenak-Kladniew, Nehuen Noacco, Nelson Duran & Guillermo R. Castro. (2022) Prodigiosin: a promising biomolecule with many potential biomedical applications. Bioengineered 13:6, pages 14227-14258.
Read now
Read now
Pawel Robak & Tadeusz Robak. (2017) Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:11, pages 1249-1265.
Read now
Read now
Maximilian Stahl & Amer M. Zeidan. (2017) Management of myelofibrosis: JAK inhibition and beyond. Expert Review of Hematology 10:5, pages 459-477.
Read now
Read now
Jennifer R. Brown, Bethany Tesar, Lijian Yu, Lillian Werner, Naoko Takebe, Evgeny Mikler, Hazel M. Reynolds, Christina Thompson, David C. Fisher, Donna Neuberg & A. S. Freedman. (2015) Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leukemia & Lymphoma 56:12, pages 3336-3342.
Read now
Read now
Jane Huang, Wayne Fairbrother & John C Reed. (2015) Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies. Expert Review of Hematology 8:3, pages 283-297.
Read now
Read now
Shadia Zaman, Rui Wang & Varsha Gandhi. (2014) Targeting the apoptosis pathway in hematologic malignancies. Leukemia & Lymphoma 55:9, pages 1980-1992.
Read now
Read now
Articles from other publishers (50)
Abhay Uthale, Aarti Anantram, Prasad Sulkshane, Mariam Degani & Tanuja Teni. (2022) Identification of bicyclic compounds that act as dual inhibitors of Bcl-2 and Mcl-1. Molecular Diversity 27:3, pages 1359-1374.
Crossref
Crossref
Margarita Espona-Fiedler, Pilar Manuel-Manresa, Cristina Benítez-García, Pere Fontova, Roberto Quesada, Vanessa Soto-Cerrato & Ricardo Pérez-Tomás. (2022) Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma. Pharmaceutics 15:1, pages 97.
Crossref
Crossref
Monica D. Reece, Colin Song, Sarah C. Hancock, Susan Pereira Ribeiro, Deanna A. Kulpa & Christina Gavegnano. (2022) Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections. Frontiers in Immunology 13.
Crossref
Crossref
Adrià Molero-Valenzuela, Pere Fontova, Daniel Alonso-Carrillo, Israel Carreira-Barral, Ana Aurora Torres, María García-Valverde, Cristina Benítez-García, Ricardo Pérez-Tomás, Roberto Quesada & Vanessa Soto-Cerrato. (2022) A Novel Late-Stage Autophagy Inhibitor That Efficiently Targets Lysosomes Inducing Potent Cytotoxic and Sensitizing Effects in Lung Cancer. Cancers 14:14, pages 3387.
Crossref
Crossref
Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. ZamyatninJrJr & Surinder M. Soond. (2021) BH3-mimetics: recent developments in cancer therapy. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Jingye Li, Jinrong Xu & Zhibing Li. (2021) Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Translational Oncology 14:8, pages 101116.
Crossref
Crossref
Fleurdeliz Maglangit, Yi Yu & Hai Deng. (2021) Bacterial pathogens: threat or treat (a review on bioactive natural products from bacterial pathogens). Natural Product Reports 38:4, pages 782-821.
Crossref
Crossref
Finny Varghese, Esther van Woudenbergh, Gijs Overheul, Marc Eleveld, Lisa Kurver, Niels van Heerbeek, Arjan van Laarhoven, Pascal Miesen, Gerco den Hartog, Marien de Jonge & Ronald van Rij. (2021) Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro. Viruses 13:2, pages 282.
Crossref
Crossref
Francisco Washington A. Barros‐Nepomuceno, Daniel Araújo Viana, Daniel Pascoalino Pinheiro, Fátima Cássia Evangelista de Oliveira, Jamile Magalhães Ferreira, Maria Goretti R. de Queiroz, Xinghua Ma, Bruno Coêlho Cavalcanti, Claudia Pessoa & Martin G. Banwell. (2020) The Effects of the Alkaloid Tambjamine J on Mice Implanted with Sarcoma 180 Tumor Cells. ChemMedChem 16:2, pages 420-428.
Crossref
Crossref
Joonas Haapasalo, Kristiina Nordfors & Seppo Parkkila. 2021. pH-Interfering Agents as Chemosensitizers in Cancer Therapy. pH-Interfering Agents as Chemosensitizers in Cancer Therapy
35
43
.
Małgorzata Opydo-Chanek, Iwona Cichoń, Agnieszka Rak, Elżbieta Kołaczkowska & Lidia Mazur. (2020) The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells. Investigational New Drugs 38:6, pages 1664-1676.
Crossref
Crossref
Tuhina Khan, Nicola Relitti, Margherita Brindisi, Stefania Magnano, Daniela Zisterer, Sandra Gemma, Stefania Butini & Giuseppe Campiani. (2019) Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. Medicinal Research Reviews 40:3, pages 1002-1060.
Crossref
Crossref
Chi-Hung R. Or, Chiao-Wen Huang, Ching-Chin Chang, You-Chen Lai, Yi-Ju Chen & Chia-Che Chang. (2020) Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling. International Journal of Molecular Sciences 21:5, pages 1773.
Crossref
Crossref
Vasanti Suvarna, Vikas Singh & Manikanta Murahari. (2019) Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. European Journal of Pharmacology 862, pages 172655.
Crossref
Crossref
Shu Yang, Yujia Mao, Huijun Zhang, Yan Xu, Jing An & Ziwei Huang. (2019) The chemical biology of apoptosis: Revisited after 17 years. European Journal of Medicinal Chemistry 177, pages 63-75.
Crossref
Crossref
Joe S. Matarlo, Lauren R.H. Krumpe, William F. Heinz, Daniel Oh, Shilpa R. Shenoy, Cheryl L. Thomas, Ekaterina I. Goncharova, Stephen J. Lockett & Barry R. O'Keefe. (2019) The Natural Product Butylcycloheptyl Prodiginine Binds Pre-miR-21, Inhibits Dicer-Mediated Processing of Pre-miR-21, and Blocks Cellular Proliferation. Cell Chemical Biology 26:8, pages 1133-1142.e4.
Crossref
Crossref
Lloyd Mabonga & Abidemi Paul Kappo. (2019) Protein-protein interaction modulators: advances, successes and remaining challenges. Biophysical Reviews 11:4, pages 559-581.
Crossref
Crossref
Thomas Steele, George Talbott, Anhao Sam, Clifford Tepper, Paramita Ghosh & Ruth Vinall. (2019) Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. International Journal of Molecular Sciences 20:6, pages 1285.
Crossref
Crossref
Clara R. L. Oudenaarden, Robert A. H. van de Ven & Patrick W. B. Derksen. (2018) Re-inforcing the cell death army in the fight against breast cancer. Journal of Cell Science 131:16.
Crossref
Crossref
Nadia Khan & Brad Kahl. (2018) Targeting BCL-2 in Hematologic Malignancies. Targeted Oncology 13:3, pages 257-267.
Crossref
Crossref
Shane Cheung, Dan Wu, Harrison C. Daly, Nathalie Busschaert, Marina Morgunova, Jeremy C. Simpson, Dimitri Scholz, Philip A. Gale & Donal F. O'Shea. (2018) Real-Time Recording of the Cellular Effects of the Anion Transporter Prodigiosin. Chem 4:4, pages 879-895.
Crossref
Crossref
Alma Abou Samra, Aude Robert, Crystal Gov, Loëtitia Favre, Laure Eloy, Eric Jacquet, Jérôme Bignon, Joëlle Wiels, Sandy Desrat & Fanny Roussi. (2018) Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A. European Journal of Medicinal Chemistry 148, pages 26-38.
Crossref
Crossref
Stepana Boukalova, Katerina Rohlenova, Jakub Rohlena & Jiri Neuzil. 2018. Mitochondrial Biology and Experimental Therapeutics. Mitochondrial Biology and Experimental Therapeutics
613
635
.
Mumtahena Rahman, Shelley M. MacNeil, David F. Jenkins, Gajendra Shrestha, Sydney R. Wyatt, Jasmine A. McQuerry, Stephen R. Piccolo, Laura M. Heiser, Joe W. Gray, W. Evan Johnson & Andrea H. Bild. (2017) Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. Genome Medicine 9:1.
Crossref
Crossref
Małgorzata Opydo-Chanek, Oscar Gonzalo & Isabel Marzo. (2017) Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects. Biochemical Pharmacology 136, pages 12-23.
Crossref
Crossref
Finny S. Varghese, Kai Rausalu, Marika Hakanen, Sirle Saul, Beate M. Kümmerer, Petri Susi, Andres Merits & Tero Ahola. (2017) Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments. Antimicrobial Agents and Chemotherapy 61:3.
Crossref
Crossref
Kate-lyn A. R. Lund, Carlotta Figliola, Aleksandra K. Kajetanowicz & Alison Thompson. (2017) Synthesis and anticancer activity of prodigiosenes bearing C-ring esters and amides. RSC Advances 7:30, pages 18617-18627.
Crossref
Crossref
Chi-Hung Or, Yachu Chang, Wei-Cheng Lin, Wee-Chyan Lee, Hong-Lin Su, Muk-Wing Cheung, Chang-Po Huang, Cheesang Ho & Chia-Che Chang. (2016) Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. International Journal of Molecular Sciences 18:1, pages 44.
Crossref
Crossref
Abdul Shukkur Ebrahim, Hussam Sabbagh, Allison Liddane, Ali Raufi, Mustapha Kandouz & Ayad Al-Katib. (2016) Hematologic malignancies: newer strategies to counter the BCL-2 protein. Journal of Cancer Research and Clinical Oncology 142:9, pages 2013-2022.
Crossref
Crossref
Małgorzata Opydo-Chanek & Lidia Mazur. (2016) Comparison of in vitro antileukemic activity of obatoclax and ABT-737. Tumor Biology 37:8, pages 10839-10849.
Crossref
Crossref
Mark K. Farrugia, Daniel B. Vanderbilt, Mohamad A. Salkeni & J. Michael Ruppert. (2016) Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses. Cancer Research 76:7, pages 1677-1682.
Crossref
Crossref
Vasileios A. Stamelos, Natalie Fisher, Harnoor Bamrah, Carolyn Voisey, Joshua C. Price, William E. Farrell, Charles W. Redman & Alan Richardson. (2016) The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization. PLOS ONE 11:3, pages e0150696.
Crossref
Crossref
Duong Nhu, Guillaume Lessene, David C. S. Huang & Christopher J. Burns. (2016) Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy. MedChemComm 7:5, pages 778-787.
Crossref
Crossref
Dirk Theile, David Allendorf, Bruno Christian Köhler, Adam Jassowicz & Johanna Weiss. (2015) Obatoclax as a perpetrator in drug–drug interactions and its efficacy in multidrug resistance cell lines. Journal of Pharmacy and Pharmacology 67:11, pages 1575-1584.
Crossref
Crossref
Nathalie Busschaert, Claudia Caltagirone, Wim Van Rossom & Philip A. Gale. (2015) Applications of Supramolecular Anion Recognition. Chemical Reviews 115:15, pages 8038-8155.
Crossref
Crossref
Chengzhi Xie, Holly Edwards, J. Timothy Caldwell, Guan Wang, Jeffrey W. Taub & Yubin Ge. (2015) Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Molecular Oncology 9:2, pages 409-421.
Crossref
Crossref
Tomasz Cierpicki & Jolanta Grembecka. (2015) Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?. Immunological Reviews 263:1, pages 279-301.
Crossref
Crossref
Sandy Desrat, Camille Remeur & Fanny Roussi. (2015) Development of an efficient route toward meiogynin A-inspired dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins. Organic & Biomolecular Chemistry 13:19, pages 5520-5531.
Crossref
Crossref
Evangeline Drink, Philippe Dugourd, Elise Dumont, Nils Aronssohn, Rodolphe Antoine & Claire Loison. (2015) Optical properties of prodigiosin and obatoclax: action spectroscopy and theoretical calculations. Physical Chemistry Chemical Physics 17:39, pages 25946-25955.
Crossref
Crossref
Lotte M.E. Berghauser Pont, Jochem K.H. Spoor, Subramanian Venkatesan, Sigrid Swagemakers, Jenneke J. Kloezeman, Clemens M.F. Dirven, Peter J. van der Spek, Martine L.M. Lamfers & Sieger Leenstra. (2014) The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes & Cancer 5:11-12, pages 445-459.
Crossref
Crossref
Sandy Desrat, Anaïs Pujals, Claire Colas, Jérémy Dardenne, Charlotte Gény, Loëtitia Favre, Vincent Dumontet, Bogdan I. Iorga, Marc Litaudon, Martine Raphaël, Joëlle Wiels & Fanny Roussi. (2014) Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. Bioorganic & Medicinal Chemistry Letters 24:21, pages 5086-5088.
Crossref
Crossref
Michaela Waibel, Gareth Gregory, Jake Shortt & Ricky W. Johnstone. (2014) Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. Current Opinion in Hematology 21:4, pages 297-308.
Crossref
Crossref
X Niu, G Wang, Y Wang, J T Caldwell, H Edwards, C Xie, J W Taub, C Li, H Lin & Y Ge. (2014) Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia 28:7, pages 1557-1560.
Crossref
Crossref
Peter S. Kim, Caroline Jochems, Italia Grenga, Renee N. Donahue, Kwong Y. Tsang, James L. Gulley, Jeffrey Schlom & Benedetto Farsaci. (2014) Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy. The Journal of Immunology 192:6, pages 2622-2633.
Crossref
Crossref
K Brinkmann & H Kashkar. (2014) Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?. Cell Death & Disease 5:3, pages e1098-e1098.
Crossref
Crossref
Longchuan BaiShaomeng Wang. (2014) Targeting Apoptosis Pathways for New Cancer Therapeutics. Annual Review of Medicine 65:1, pages 139-155.
Crossref
Crossref
S. Desrat, C. Remeur, C. Gény, G. Rivière, C. Colas, V. Dumontet, N. Birlirakis, B. I. Iorga & F. Roussi. (2014) From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins. Chemical Communications 50:62, pages 8593.
Crossref
Crossref
David Wroblewski, Chen Chen Jiang, Amanda Croft, Margaret L. Farrelly, Xu Dong Zhang & Peter Hersey. (2013) OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis. PLoS ONE 8:12, pages e84073.
Crossref
Crossref
Bruno Christian Koehler, Anna-Lena Scherr, Stephan Lorenz, Toni Urbanik, Nicole Kautz, Christin Elssner, Stefan Welte, Justo Lorenzo Bermejo, Dirk Jäger & Henning Schulze-Bergkamen. (2013) Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro. PLoS ONE 8:10, pages e76446.
Crossref
Crossref
Michael Hallek. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology 88:9, pages 803-816.
Crossref
Crossref